Gilead Sciences (NASDAQ:GILD) Given New $123.00 Price Target at Morgan Stanley
Gilead Sciences (NASDAQ:GILD – Free Report) had its price objective boosted by Morgan Stanley from $113.00 to $123.00 in a research note issued to investors on Wednesday,Benzinga reports. Morgan Stanley currently has an overweight rating on the biopharmaceutical company’s stock. Other analysts have also issued reports about the stock. JPMorgan Chase & Co. upped their […]
Gilead Sciences (NASDAQ:GILD – Free Report) had its price objective boosted by Morgan Stanley from $113.00 to $123.00 in a research note issued to investors on Wednesday,Benzinga reports. Morgan Stanley currently has an overweight rating on the biopharmaceutical company’s stock. Other analysts have also issued reports about the stock. JPMorgan Chase & Co. upped their […]
